• E-mail
• Print
• Comment
• Font Size
• Digg
• del.icio.us
• Discuss article

Daxor Announces Prince George's Hospital Center of Cheverly, MD Acquires BVA-100 Blood Volume Analyzer

Posted on: Wednesday, 14 March 2007, 09:01 CDT

Daxor Corporation (AMEX: DXR), a medical instrumentation and biotechnology company, today announced the receipt of a signed trial agreement from Prince George's Hospital Center of Cheverly, Maryland.

Prince George's Hospital Center was founded in 1944 and is a 290-bed acute care teaching hospital and regional referral center. It is a member of the Dimensions Healthcare System, the largest not-for-profit provider of healthcare services in Prince George's County.

As one of the largest employers in Prince George's County, Prince George's Hospital Center provides a comprehensive range of inpatient and outpatient medical and surgical services including: the designated regional trauma center for southern Maryland; a comprehensive cardiac care program unique to Prince George's county; open-heart surgery and therapeutic catheterization; level III neonatal intensive care and perinatal diagnostic center; comprehensive outpatient services; and an intensive services pavilion housing 10 operating suites, 24-bed intensive care unit, catheterization labs and endoscopy suites.

Daxor's Blood Volume Analyzer BVA-100 will be located within Prince George's Hospital Center's Nuclear Medicine Department, and will be utilized to diagnose a variety of patient blood volume derangements.

Other nationally renowned hospitals which have purchased the BVA-100 Blood Volume Analyzer after using it on a clinical trial basis are The Mayo Clinic, The Cleveland Clinic, and New York University Medical Center. Daxor Corporation manufactures and markets the BVA-100, a semi-automated Blood Volume Analyzer. The BVA-100 is used in conjunction with Volumex, Daxor's single use diagnostic kit. For more information regarding Daxor Corporation's Blood Volume Analyzer BVA-100, visit Daxor's website www.Daxor.com.

 Contact Information:  Stephen Feldschuh Chief Operating Officer 212-330-8515 Contact via http://www.marketwire.com/mw/emailprcntct?id=8AACC7066C204334  Diane Meegan Investor Relations 212-330-8512 Contact via http://www.marketwire.com/mw/emailprcntct?id=C39D29E94C76D2A4  

SOURCE: Daxor Corp.

Source: MARKET WIRE

More News in this Category